• 1
    Savès M, Vandentorren S, Daucourt V et al. Severe hepatic cytolisis incidence and risk factors in patients treated by antiretroviral combination. Aquitaine Cohort, France, 1996–98. AIDS 1999; 13: 115.
  • 2
    Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy. Role of hepatitis C and B infections. Hepatology 2002; 35: 182189.
  • 3
    Rancinan C, Neau D, Savès M et al. Is hepatitis C co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002; 16: 13571362.
  • 4
    Den Brinker M, Wit FW, Wertheim-van Dillen PM et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 28952902.
  • 5
    Martinez E, Blanco JL, Arnaiz J et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 12611268.
  • 6
    Bonfanti P, Landonio S, Ricci E et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 316318.
  • 7
    Sukkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc 2000; 283: 7480.
  • 8
    Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002; 34: 12591263.
  • 9
    Orenstein R, Tsogas N. Looking beyond highly active antiretroviral therapy: drug-related hepatoxicity in patients with human immunodeficiency virus infection. Pharmacotherapy 2002; 22: 14681478.
  • 10
    Bonnet F, Lawson-Ayayi S, Thiebaut R, Ramanampamionjy R, Lacoste D, Bernard N. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997–99. Clin Infect Dis 2002; 35: 12311237.
  • 11
    Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia, E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998; 12: 116117.
  • 12
    John M, Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with protease inhibitors: an immune restoration disease? AIDS 1998; 12: 22892293.
  • 13
    Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? J Am Med Assoc 1998; 280: 7277.
  • 14
    Kaletra (Lopinavir/Ritonavir) Product Monograph. Abbott Laboratories, 2001: 55–56.
  • 15
    Arribas J, Barra C, Gonzales-Lahoz J et al. Treatment of HIV+ subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT-378/ritonavir vs. Nelfinavir from a phase III blinded randomized clinical trial. 5th International Congress on Drug Therapy in HIV Infection Glasgow, October 2000 [Abstract P369].
  • 16
    Bernstein B, King M, Cernohous P, Moseley J, Sun E. Treatment of HIV subjects co-infected with hepatitis B or C: week 60 safety and efficacy comparison of LPV/r vs. Nelfinavir from a phase III blinded randomized clinical trial. 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, October 2001 [Abstract P228].
  • 17
    Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 18
    Ishak K. Pathologic features of chronic hepatitis. A review and update. Am J Clin Pathol 2000; 113: 4055.
  • 19
    Bonfanti P, Valsecchi L, Parazzini F et al. Incidence of adverse reaction in HIV patients treated with protease inhibitors: a cohort study. J Acquir Immune Defic Syndr 2000; 23: 236244.
  • 20
    Gisolf EH, Dreezen C, Danner SA, Well JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 2000; 31: 12341239.
  • 21
    Monforte A, Burgarini R, Pezzotti P et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001; 28: 114123.
  • 22
    Soriano V, Kirck O, Antunes F et al. The influence of hepatitis C on the prognosis of HIV-infected persons: the EuroSIDA study XIIIth International AIDS Conference. Durban, July 2000 [Abstract Th.OrB655].
  • 23
    Thomas D. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36: S201S209.
  • 24
    Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV infected patients. Prevalence and prognostic value. J Hepatol 1997; 27: 1824.
  • 25
    Marusawa H, Uemoto S, Hijikata M et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488495.
  • 26
    Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283287.
  • 27
    Nunez M, Rios P, Martin-Carbonero L, Perez-Olmeda M, Gonzales Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30: 6568.
  • 28
    Khalili M, Behm BW. Hepatitis C in the setting of HIV co-infection. Microbes Infect 2002; 4: 12471251.
  • 29
    Martin-Carbonero L, Nunez M, Rios P, Perez-Olmeda M, Gonzales-Iahoz J, Soriano V. Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 2002; 16: 14231425.
  • 30
    Chisari FV, Ferrari C. Viral hepatitis. In: Nathanson N, ed. Viral Pathogenesis. Philadelphia, Lippincott-Raven Publishers, 1997: 745–778.
  • 31
    Minutello MA, Pileri P, Unutmaz D et al. Compartmentalization of T-lymphocyte to the site of disease: intrahepatic CD4+ T-cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis. J Exp Med 1993; 178: 1725.
  • 32
    Arribas J, Pulido F, Peng JZ et al. Evaluation of the multiple-dose pharmacokinetics of lopinavir/ritonavir in HIV and HCV co-infected subjects with mild or moderate hepatic insufficiency. 9th European Aids Conference Warsaw, 25–29 October 2003 [Abstract F2/6].
  • 33
    Gonzales de Requena D, Nunez M, Gonzales-Lahoz J, Soriano V. Liver toxicity of lopinavir/ritonavir containing regiments in HIV infected patients with or without hepatitis C virus (HCV) co-infection. 9th European Aids Conference Warsaw, 25–29 October 2003 [Abstract 9.6/1].